Updated 12-month follow-up results may support regulatory progress for its lead oncology candidate.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) reported updated Phase 2b data from its CLOVER WaM study, showing durable responses for iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia (WM). For investors, the results may strengthen the company’s case for accelerated approval and highlight progress toward potential commercialization.
Key Investor Takeaways
- Cellectar (NASDAQ:CLRB) released Phase 2b data showing strong response rates and durability in WM patients.
- The study achieved its primary endpoint (61.8% major response rate) and demonstrated sustained responses over 12 months.
- Results support potential accelerated regulatory submission, with a confirmatory trial planned.
- Strong efficacy was observed in BTKi-exposed and refractory patients, a difficult-to-treat population.
- The program addresses a high unmet need, with limited approved treatment options after BTKi failure.
Press Release Overview
The CLOVER WaM Phase 2b trial evaluated iopofosine I 131 in 55 heavily pretreated WM patients, all of whom had at least 12 months of follow-up.
Key efficacy results included:
- Overall Response Rate (ORR): 83.6%
- Major Response Rate (MRR): 61.8% (primary endpoint achieved)
- Median Duration of Response (DoR): 17.8 months
- Median Progression-Free Survival (PFS): 13.5 months
- Disease Control Rate (DCR): 98.2%
In subgroup analyses:
- BTKi-exposed patients showed a 64.1% MRR and 18.2-month median DoR
- BTKi-refractory patients showed a 63.6% MRR and similar durability
The company reported that safety remained consistent, with manageable adverse events and no significant bleeding issues.
Cellectar stated the dataset meets FDA expectations for accelerated approval, supported by durable responses and completed follow-up. The company plans to initiate a confirmatory randomized study in the fourth quarter of 2026.
Why This Matters for Investors
The updated Phase 2b data reinforces the clinical profile of iopofosine I 131, particularly its durability and activity in heavily pretreated patients. This may strengthen the company’s position as it moves toward regulatory submission.
The ability to demonstrate efficacy in BTKi-exposed and refractory patients could differentiate the therapy in a setting with limited treatment options. If successful, this may support adoption in later-line WM treatment.
However, regulatory approval is not guaranteed, and the confirmatory study will be critical in validating long-term clinical benefit. Investors may also consider the competitive landscape and potential commercialization challenges.
What to Watch For Next
- Progress toward accelerated approval submission in the U.S. and Europe
- Initiation and design of the confirmatory clinical trial
- Additional data presentations at ASCO and other conferences
- Regulatory feedback and potential timeline updates
- Future clinical results across other pipeline indications
Conclusion
Cellectar’s Phase 2b data highlights encouraging efficacy and durability for iopofosine I 131 in Waldenström macroglobulinemia. While the results may support regulatory progress, investors are likely to focus on upcoming submissions and confirmatory trial outcomes to assess the therapy’s long-term potential.